OncoMatch

OncoMatch/Clinical Trials/NCT03533816

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Is NCT03533816 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including EAGD T-cell infusion (Phase I) and EAGD T-cell infusion (Expansion) for acute myeloid leukemia.

Phase 1RecruitingUniversity of Kansas Medical CenterNCT03533816Data as of May 2026

Treatment: EAGD T-cell infusion (Phase I) · EAGD T-cell infusion (Expansion) — Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partially mismatched bone marrow transplant (haploidentical).

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Chronic Myeloid Leukemia

Acute Lymphoblastic Leukemia

Myelodysplastic Syndrome

Lab requirements

Kidney function

serum creatinine <2 mg/dl AND estimated (Cockcroft-Gault formula) or measured creatinine clearance (CrCl) ≥70 mL/min/1.73 m2

Liver function

serum bilirubin 1.5 upper limit of normal (ULN), AST/ALT 2.5 ULN, and alkaline phosphatase 2.5 ULN

Cardiac function

Normal left ventricular ejection fraction (LVEF) (50% or above) as measured by MUGA or Echocardiogram

Organ Function Criteria: Cardiac: Normal left ventricular ejection fraction (LVEF) (50% or above) as measured by MUGA or Echocardiogram. Pulmonary: FVC, FEV1 and DLCO (corrected) should be 50% or above of expected. Renal: serum creatinine level to be <2 mg/dl AND estimated (Cockcroft-Gault formula) or measured (takes priority if done) creatinine clearance (CrCl) must be equal or greater than 70 mL/min/1.73 m2. Hepatic: serum bilirubin 1.5 upper limit of normal (ULN), Aspartate transaminase (AST)/alanine transaminase (ALT) 2.5 ULN, and alkaline phosphatase 2.5 ULN.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University of Kansas Cancer Center · Westwood, Kansas
  • Ohio State University Medical Center · Columbus, Ohio

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify